Drug Profile
Censavudine - Transposon Therapeutics
Alternative Names: 4'-Ethynyl-d4T - Transposon Therapeutics; 4'-ethynylstavudine; BMS-986001; Ed4T; Festinavir; OBP-601; TPN-101Latest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Kagoshima University; Showa University; Yale University
- Developer Oncolys BioPharma; Transposon Therapeutics
- Class Antidementias; Antivirals; Furans; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Aicardi-Goutieres syndrome; Amyotrophic lateral sclerosis; Frontotemporal dementia; Progressive supranuclear palsy
- Discontinued HIV-1 infections
Most Recent Events
- 13 Feb 2024 Efficacy data from a phase IIa trial in Progressive supranuclear palsy released by Transposon Therapeutics
- 13 Feb 2024 Efficacy data from phase II trial in Amyotrophic Lateral Sclerosis and Frontotemporal dementia released by Transposon Therapeutics
- 13 Feb 2024 Transposon Therapeutics plans a phase III registration study for Amyotrophic lateral sclerosis, Frontotemporal dementia and Progressive supranuclear palsy